After Sputnik V, Russia now has a second Covid-19 vaccine, says Putin | WeForNews | Latest News, Blogs After Sputnik V, Russia now has a second Covid-19 vaccine, says Putin – WeForNews | Latest News, Blogs
Connect with us

Health

After Sputnik V, Russia now has a second Covid-19 vaccine, says Putin

Russia in August became the first country to grant regulatory approval for a Covid-19 vaccine, doing so before large-scale trials were complete

Published

on

Covid 19 Vaccine

Russia has granted regulatory approval to a second Covid-19 vaccine, a delighted President Vladimir Putin announced at a government meeting on Wednesday.

Putin congratulated scientists for approving the new jab, which was developed by Siberia’s Vector Institute and completed early-stage human trials last month.

“We need to increase production of the first and second vaccine,” he said in comments broadcast on state TV.

“We are continuing to cooperate with our foreign partners and will promote our vaccine abroad.”

Russia in August became the first country to grant regulatory approval for a Covid-19 vaccine, doing so before large-scale trials were complete, to the concern of some in the global scientific community.

About 400 high-risk patients have received that jab, according to the health ministry. The vaccine, called “Sputnik V” in homage to the world’s first satellite launched by the Soviet Union, is not yet in general circulation.

Since the start of the pandemic, Russia has recorded 1,340,409 infections, the fourth largest number of cases in the world behind the United States, India and Brazil.

Health

Coronavirus: India inches closer to 93 Lakh Covid-19 cases

Apart from Maharashtra, Andhra Pradesh, and Karnataka have reported the highest number of cases.

Published

on

By

Coronavirus India

New Delhi, Nov 26 : With 44,489 new cases of Covid infections, India’s total cases reached 92,66,705 on Thursday. It is the 19th straight day when India reported less than 50,000 cases in a day.

The last time daily new cases crossed the 50,000-threshold was on November 7.

According to the data released by the Ministry of Health and Family Welfare, 524 new deaths occurred due to the deadly virus in the last 24 hours taking the toll to 1,35,223.

While the active cases stood at 4,52,344, a total of 86,79,138 have recovered from the virus and have been discharged of which 36,367 were discharged in the last 24 hrs.

While the recovery rate stands at 93.66 per cent, the fatality rate is at 1.46 per cent, the Ministry data revealed.

Maharashtra remains the worst-hit state with 84,464 active cases and 46,748 deaths so far. The recoveries in the state stand at 17,95,959.

Apart from Maharashtra, Andhra Pradesh, and Karnataka have reported the highest number of cases.

The National capital is also witnessing a surge.

Continue Reading

Blog

Global availability of Covid vaccine for public only by mid-2021: Moody’s

The report said mass vaccination that significantly reduces individual and public health concerns would lift sentiment and present a significant upside to global growth.

Published

on

By

Covid 19 Vaccine

New Delhi: While recent news about the high effectiveness of two coronavirus vaccines is a promising sign in the effort to combat the pandemic, a vaccine for Covid-19 will not be widely distributed before mid-2021, Moodys Investors Service said on Tuesday.

“However, these developments do not change the assumption underpinning our economic forecasts that widespread, global availability of the vaccine to the general public is only likely by around mid-2021,” Moody’s said in a report.

It added that the recent positive news about the effectiveness of vaccines under development will do little to ease the immediate concern that the current rise in coronavirus cases across the US and Europe will dampen sentiments and economic momentum in these regions this quarter and the next.

“Our baseline economic forecasts balance the downside risks of increasing infections and new lockdowns in the next two months, against the potential for widespread vaccinations over the next 12 months. If lockdowns are more severe than we expect, the negative effect on GDP could be offset if a coronavirus vaccine is available quicker and uptake is wider than we had expected,” it added.

Although successful Phase 3 trials of vaccines are a big step, there are numerous hurdles ahead, including satisfying approval requirements by regulators in individual countries, production of the billions of doses required for mass vaccination, ensuring proper storage and building distribution networks.

Distribution will likely occur in phases once regulators approve a vaccine, with health officials prioritizing access for healthcare workers and those in other high-risk professions, as well as for people who are most vulnerable to COVID-19, such as older people and individuals in care homes.

Moody’s said two important variables in overall success of vaccines in curbing the pandemic will be the public’s willingness to get vaccinated and what percentage of the population will need to be vaccinated in order for the spread of the virus to be brought under control. Vaccine availability likely will vary across countries, with cost and access major hurdles in particular for less-developed economies.

Many advanced and a handful of middle-income emerging market countries have already secured contracts for hundreds of millions of doses of the vaccines. Residents of these countries will be among the first to get the vaccinations, with their economies benefiting from the associated easing of the public health crisis. The earlier the health crisis in a country subsides, the stronger the country’s economic recovery will be, it added.

The report said mass vaccination that significantly reduces individual and public health concerns would lift sentiment and present a significant upside to global growth.

As long as the coronavirus remains a health risk, social distancing restrictions and the reluctance of consumers to engage in high contact social and economic activity will mar the recovery of services sectors. As vaccines become broadly available, health fears and concerns about an uncertain economic and financial outlook should recede, allowing for a quicker resumption of activity in high contact sectors such as hotels, restaurants, theaters, mass transit, airlines and travel and tourism.

Moody’s said the pandemic has already inflicted enormous damage on the hardest-hit sectors and will continue to undermine their financial condition and prospects, with repeated virus outbreaks and lockdown measures suppressing demand. The risk of business failure increases exponentially the longer the pandemic prevents a return to some semblance of normal activity.

A vaccine will help accelerate the recovery. But for many of these businesses, survival will remain challenging until the virus is no longer viewed as a significant public health threat. It is difficult to know how many businesses will survive several more months of below-normal revenue, it added.

Small and midsized businesses across advanced and emerging market countries are at risk and more of them will undoubtedly close on account of the prolonged cash flow shock. And those that do survive will have the long and arduous task of rebuilding their balance sheets while also, in many cases, facing significant changes in consumer behavior and demand patterns. “Therefore, even if economic activity returns to healthy levels once a vaccine is widely available, the detrimental economic impact and transformed operating environment will be felt for years to come”, Moody’s said.

Continue Reading

Health

Saudi Arabia to make COVID-19 vaccine free for citizens and residents

As per Gulf News, Dr Asiri told Al Ekhbariya that Saudi Arabia will receive vaccines through COVAX facility as well as through companies outside of the consortium.

Published

on

By

Saudi King Salman

Abu Dhabi: Saudi Arabia’s Health Ministry on Monday announced that it would make the coronavirus vaccine available for free to all citizens and residents.

“Those who have not tested positive for COVID-19 will be given priority in the vaccine campaign in the coming months,” said Dr Abdullah Asiri, the assistant undersecretary at the ministry.

He, however, added that those below 16 years of age will not be vaccinated unless research proves otherwise.

As per Gulf News, Dr Asiri told Al Ekhbariya that Saudi Arabia will receive vaccines through COVAX facility as well as through companies outside of the consortium.

“The Kingdom worked on two paths to obtain the vaccine, through the COVAX organisation, which the G20 had a role in creating and financing…Saudi Arabia will obtain a large number of vaccines through this facility, while the second track is directly contracting with the big companies to cover the gap that cannot be covered through COVAX,” Arab News mentioned Asiri as saying.

According to the World Health Organization, “the COVAX facility forms a key part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.”

The Saudi Health Ministry further expected that by the end of next year, the vaccines would cover 70 per cent of the Kingdom’s population.

“One of the most important goals set by the G20 during Saudi Arabia’s G20 presidency is to support all-inclusive and equitable access to vaccines, diagnostic and treatment tools,” said Dr Abdullah Asiri.

Dr Asiri added that a comprehensive plan for vaccine distribution will be ready “in the coming weeks”.

During the two-day G20 summit hosted virtually in Riyadh, Dr Abdullah Al Rabeeah, the supervisor general of the King Salman Humanitarian Aid and Relief Centre, on Friday said that his country would be among the first ones to get hold of a COVID-19 vaccine.

Dr Al Rabeeah added that Saudi Arabia has spent over USD 200 million on COVID-19 vaccine and drug development.

Saudi King Salman bin Abdulaziz had in March also ordered free coronavirus treatment for all citizens.

Meanwhile, WHO director-general Tedros Adhanom Ghebreyesus on Monday announced: “There is now real hope that vaccines, in combination with other tried and tested public health measures, will help to end the pandemic.”

His remarks came after drugmaker AstraZeneca announced that its COVID-19 vaccine was up to 90 per cent effective. With this, AstraZeneca has become the third major drug company after Pfizer and Moderna to have reported late-stage data for a potential COVID-19 vaccine.

“The significance of this scientific achievement cannot be overstated. No vaccines in history have been developed as rapidly as these. The scientific community has set a new standard for vaccine development,” added Tedros.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.